Using ADAPT to Optimize Type 2 Diabetes Pharmacotherapy

Antihyperglycemic Drug Algorithm For Pharmacotherapy in Type 2 Diabetes

MDBriefCase and AstraZeneca have partnered to bring healthcare providers a first-of-its-kind decision support tool that can help to transform diabetes care in the Kingdom. The ADAPT (Antihyperglycemic Drug Algorithm For Pharmacotherapy in Type 2 Diabetes) program will provide healthcare providers with evidence-based guidance from the American Diabetes Association, with a focus on optimizing pharmacotherapy in type 2 diabetes beyond glucose control. ADAPT will be introduced as a tool for healthcare providers to support patient assessment and to guide selection of pharmacotherapy. The goal is to engage healthcare providers in the use of ADAPT to optimize pharmacotherapy in people with type 2 diabetes.

Planning Committee:

Dr. Ronald Goldenberg, MD, FRCPC
Dr. Raed Aldahash, MD, F.A.C.E

How it works

Complete a 15-minute online continuing medical education (CME) program to become familiar with evidence-based guidance from the American Diabetes Association Standards of Medical Care in Diabetes – 2022, with a focus on optimizing pharmacotherapy in type 2 diabetes. Note: The link to the CME will be shared with you once it has been made available.
Watch the eTraining video within the CME that will demonstrate how to access and use the ADAPT tool to support your patient assessments and pharmacotherapy selections.
Submit a request to indicate your interest in using the ADAPT tool. To receive access to the tool, please fill out the registration and consent form below.
Receive an email when your ADAPT tool account is ready. Reset your password.
Login and use the tool to support your clinical practice!

Have questions?

For questions related to the ADAPT program, please contact Mohamed Hamdy Hussein Naguib at Mohamed.Hamdy@astrazeneca.com.

This program has received financial support from AstraZeneca in the form of an unrestricted educational grant.